Sains Malaysiana 47(10)(2018): 2429–2435
http://dx.doi.org/10.17576/jsm-2018-4710-19
Graveoline from Ruta angustifolia (L.) Pers. and Its Antimicrobial Synergistic
Potential in Erythromycin or Vancomycin Combinations
(Graveolin daripada Ruta angustifolia (L.) Pers. dan Potensi Sinergistik
Antimikrobnya dalam Gabungan Erithromicin atau Vancomicin)
LAINA ZARISA MOHD KAMAL, NORAZIAN MOHD HASSAN*, NURHAYA MD TAIB & MAY KHIN SOE
ABSTRACT
Ruta angustifolia (L.) Pers. is a Rutaceous species which contains various anthranilic acid derived alkaloids including
the bioactive quinolones. This study is aimed at identifying the antimicrobial active alkaloids of R. angustifolia and
evaluating their potential as synergistic enhancers in alkaloid-antibiotic combinations. Antimicrobial bioautographyguided isolation of alkaloidal fractions of R. angustifolia leaves has led to the identification of 2,3-dimethoxy-1-hydroxy10-methylacridone [arborinine]; and 4,7,8-trimethoxyfuro[2,3-b]quinoline [skimmianine]; together with the major
active alkaloid, 1-methyl-2-[3’,4’-methylenedioxyphenyl]-4-quinolone [graveoline]. Graveoline showed Minimum
Inhibitory Concentration (MIC) values ranging from 500 to 1000 µg/mL against Staphylococcus aureus ATCC 25923,
Enterococcus faecalis ATCC 29212 and Escherichia coli ATCC 25922. Checkerboard assay for antimicrobial combination
effects between graveoline with either erythromycin or vancomycin showed enhancement of the antimicrobial activity
of both antibiotics with Fractional Inhibitory Concentration Indices (FICI) ranged from 0.37 to 1.50. Synergistic effect
with FICI of 0.37 was observed for graveoline-erythromycin combination against S. aureus compared to FICI of 1.00 for
ciprofloxacin-erythromycin additive effect. Graveoline was a potential candidate for antimicrobial combination agent
especially against S. aureus. The result supports the idea of using plant metabolites as antimicrobial synergistic agents.
Keywords: Antimicrobial; graveoline; Ruta angustifolia; synergistic enhancer
ABSTRAK
Ruta angustifolia (L.) Pers. adalah spesies Rutaceae yang mengandungi pelbagai alkaloid yang hasilkan daripada asid
anthranilik seperti alkaloid quinolon. Kajian ini bertujuan untuk mengenal pasti alkaloid aktif daripada R. angustifolia
dan potensinya sebagai penggalak kesan sinergi bersama antibiotik terpilih. Pemencilan alkaloid aktif berpandukan
bioautografi antimikrob daripada pecahan ekstrak daun R. angustifolia berjaya mengenal pasti 2,3-dimetoksi-1hidroksi-10-metilakridon [arborinin]; dan 4,7,8-trimetoksifuro[2,3-b]quinolin [skimmianin]; dan akaloid aktif utama
1-metil-2-[3’,4’-metilenedioksifenil]-4-quinolon [graveolin]. Graveolin menunjukkan Kepekatan Perencatan Minima
(MIC) pada julat antara 500 dan 1000 µg/mL terhadap Staphylococcus aureus ATCC 25923, Enterococcus faecalis ATCC
29212 dan Escherichia coli ATCC 25922. Gabungan antara graveolin dan erithromicin atau vankomicin yang dinilai
melalui Assay Checkerboard menunjukkan bahawa graveolin meningkatkan aktiviti kedua-dua antibiotik dengan Indeks
Pecahan Kepekatan Perencatan (FICI) antara 0.37 dan 1.50. Kesan sinergi dengan nilai FICI 0.37 ditunjukkan oleh
gabungan graveolin-erithromicin terhadap S. aureus berbanding kesan tambahan dengan nilai FICI 1.00 oleh gabungan
ciprofloxacin-erithromicin. Graveolin mempunyai potensi sebagai agen gabungan antimikrob terutama terhadap S.
aureus. Keputusan kajian ini menyokong penggunaan metabolit daripada tumbuhan sebagai agen sinergi antimikrob.
Kata kunci: Antimikrob; graveolin; penggalak sinergistik; Ruta angustifolia
INTRODUCTION
The resistance in current antibiotics which restricts their
effectiveness in the standard treatment of infections
has dramatically increasing due to global emergence
of multi-drug resistant bacterial strains. The global
concern on the present updates on widespread antibiotic
resistance include treatment failure of Escherichia
coli, Klebsiella pneumoniae, Staphylococcus aureus
and Enterobacteriaceae infections to fluroquinolones,
carbapenem, the first line drugs treatment and colistin,
respectively. Erythromycin, vancomycin and ciprofloxacin
are among the antibiotics which are prone to be degraded
by the bacterial enzymatic resistance mechanism (WHO
2017). One of the strategies employed in overcoming
limited number of antimicrobial agents that are currently
available in fighting the highly resistant strains is antibiotic
combination therapy (Tamma et al. 2012).
Plant-based natural product is one of the ideal
candidates in discovering new class of antimicrobial agent
and has contributed in surviving the increasing number of
bacterial resistance towards currently existing antibiotics
(Abreu et al. 2012). These phytochemicals are potential
2430
antimicrobial combination agents since several compounds
have also been found to be synergistic enhancers (Kyaw et
al. 2012; Linda et al. 2011). Although they may possessed
weak inhibitory activity alone but when combined
with certain antibiotics they enhanced the activity of
the later (Kyaw et al. 2012). The combination also has
been recognised as important approach for delaying the
emergence of bacterial resistance and may also eventually
reduced the undesirable side effects of the antibiotics
(Hemaiswarya & Doble 2010).
Rutaceae has been a source of interest for its novel
anthranillic acid derived alkaloids with biologically
active antibacterial and antifungal properties (da Silva et
al. 2013). Ruta angustifolia (Garuda or Aruda in Malay)
of the Rutaceae is one of the rich sources of anthranilic
acid derived alkaloids including acridone, quinoline,
quinolone and furoquinoline alkaloids (El Sayed et al.
2003). It is a small shrub with strong and unpleasant smell
and used traditionally for treating ear infection, boils and
bruised (Shamsul et al. 2003). Alkaloids are among the
bioactive phytochemicals which are responsible for the
antimicrobial activity possessed by Ruta species (Raj et
al. 2013). The reported alkaloids of R. angustifolia include
rutaverine, arborinine, fagarine, graveolinine, graveoline
and skimmianine (Koh et al. 2009). The present study
was undertaken to isolate and identify the antimicrobial
active alkaloids of R. angustifolia, and evaluating their
potential as synergistic enhancers in alkaloid-antibiotic
combinations with either erythromycin or vancomycin.
MATERIALS AND METHODS
INSTRUMENTATIONS
Spots on TLC chromatograms were visualized under UV
lights at 254 and 365 nm by using Fluorescent Analysis
Cabinet (SPECTROLINE, CM-10). Alkaloid purification was
performed using chromatotron (Model 7924T, Harrison
Research U.S.A) with silica gel containing gypsum Kieselgel
60 PF254 (Merck, 7749) as the stationary phase. Melting
point was determined using digital melting point apparatus
(Stuart’s SMP20) equipped with microscope. Ultraviolet
spectra were recorded in methanol using HITACHI, U-2900
Spectrophotometer. The infrared spectra were recorded
on Perkin Elmer FTIR Spectrum 2000 Spectrometer with
chloroform as solvent. 1H NMR and 13C NMR spectra were
recorded on a Bruker, 500 MHz (Avance III, Ultrashield
Plus) Spectrometer. MS were recorded by direct probe
method using Thermofinnigan Trace GC-Polaris-Q GCMS.
PLANT MATERIALS
Ruta angustifolia (L.) Pers. was purchased at Muar, Johor,
Malaysia. The plant species was verified by Dr. Shamsul
Khamis, the botanist of Herbarium, Universiti Kebangsaan
Malaysia (UKMB). A voucher specimen (PIIUM 0002-1)
was deposited at the Herbarium, Kulliyyah of Pharmacy,
International Islamic University Malaysia.
EXTRACTION
The dried leaves (400 g) were defatted with hexane and
then extracted with acetone (4 L) using soxhlet apparatus.
The extract was concentrated to 1/8 of its original volume
and extracted exhaustively with 2% hydrochloric acid until
Mayer’s test became negative. The acidic aqueous solution
was basified with 0.5 M sodium hydroxide to pH8-9 and
extracted with CHCl3 until extinction. The crude alkaloidal
extract was then dried using sodium sulphate anhydrous,
filtered and evaporated to dryness (7.1 g).
FRACTIONATION AND ISOLATION
The extract (2.6 g) was fractionated by column
chromatography on silica gel (100 g, 70-230 mesh)
(column 3 × 100 cm) eluting successively with hexane/
CH2Cl2 (4:6 - 0:1, 5% increment of CH2Cl2), then CH2Cl2/
EtOAc (9:1 - 1:1, 10% increment of EtOAc) and a gradient
of CH2Cl2/EtOAc/Me2CO (10:9:1-2:7:1, 10% and 1%
increment of EtOAc and Me2CO, respectively, to furnished
10 fractions (F1 - F10). Fractions F3, F4 and F10 were
subjected to bioautography agar overlay assay which
showed RA2, RA3 and RA9 as the antimicrobial active
alkaloids. Fraction F3 (50 mg) was rechromatographed by
column chromatography (40 g) (column 2 × 40 cm) with
hexane/CH2Cl2 (4:6-2:8, 1% increment of CH2Cl2 then
1-2% of EtOAc) to give 3 fractions (F3-1 - F3-3). Fraction
F3-3 (150 mg) was further purified by chromatotron (1
mm thickness) with 100% pet-ether then a gradient of
pet-ether/CH2Cl2 (99:1-8:2, 1% increment of CH2Cl2 then
1% increment of EtOAc with subsequent 1% decrement of
CH2Cl2. RA2 or arborinine (1) was eluted with pet-ether/
CH2Cl2/EtOAc (80:6:14) (30 mg, 1.2%). A total of 20
mg Fraction F4 was separated by chromatotron (1 mm
thickness) with mixture of RA3 or skimmianine (2) (0.8
mg, 0.03%) was purified from fraction F4 (20 mg) by
using chromatotron (1 mm thickness) eluted with pet-ether/
CH2Cl2/EtOAc (80:11:9) at the flow rate of 2 to 3 mL/min.
Fraction F10 (120 mg) was rechromatographed on silica
gel (15 g) (column 2 × 20 cm) eluting consecutively with
pet-ether/CH2Cl2 (1:1 - 0:1, 10% increment of CH2Cl2) and
CH2Cl2/MeOH (99:1 and 98:2). RA9 or graveoline (3) was
eluted with CH2Cl2/MeOH (98:2) (80 mg, 3.1%).
ANTIMICROBIAL ACTIVITY
TEST MICROORGANISMS
Three bacterial strains of American Type Culture
Collection (ATCC), namely Staphylococcus aureus ATCC
25923, Escherichia coli ATCC 25922 and Enterococcus
faecalis ATCC 29212 were used in this study.
INOCULA FOR ANTIMICROBIAL TESTS
The inocula for antimicrobial testing were prepared
according to Rahalison et al. (1991). The inoculum size
of 18 h culture incubated at 37°C was adjusted by using
2431
spectrophotometer to an absorbance of 0.11 to 0.12
at 600 nm.
UV
BIOAUTOGRAPHY AGAR OVERLAY ASSAY
This assay was performed according to the bioautographic
procedures (Rahalison et al. 1991) with a few modifications.
All fractions were chromatographed on 4 cm × 10 cm
TLC commercial aluminium sheets Silica gel 60F254 of
layer thickness 0.2 mm. The chromatogram was rapidly
distributed with 5 mL of inoculated molten agar at 35°C.
After solidification of the agar, the TLC plates were kept
in sterile petri dishes lined with moist filter papers and
incubated at 37°C for 24 h. The plates were sprayed
with an aqueous solution of 0.5% 2-[4-iodo-phenyl]-3[4-nitrophenyl]-5-phenyl-tetrazolium chloride (INT) and
reincubated for 4 h. The active alkaloids were detected
as the clear zones against a pink background of viable
microbes. The reference chromatograms were visualized
under UV lights and sprayed with Dragendorff’s reagent.
BROTH MICRODILUTION ASSAY
The minimum inhibitory concentrations ( MIC s) of
graveoline and selected antibiotics were determined
in triplicate against the test microorganisms by broth
microdilution assay following the Clinical and Laboratory
Standards Institute ( CLSI ) 2006 method with some
modifications. Stock solution of gaveoline was twofold serially diluted in 96 well microtiter plate to obtain
concentrations ranging from 1.56 to 1000 µg/mL. Standard
antibiotics were prepared at a few ranges of concentrations
from 0.48 to 500 µg/mL by two-fold serial dilution of two,
five or ten times diluted stock solution of 1000 µg/mL.
The microbial inocula were diluted hundred times to an
approximate concentration of 1 × 105 colony forming unit
(CFU)/mL with sterile broth. Each well contained a final
volume of 200 µL of 180 µL of inoculated broth and 20
µL of tested solution. The assay was repeated with diluents
to check their effects on bacterial growth. Wells with
bacterial suspension and uninoculated broth are included
as normal growth and sterility control, respectively. The
plates were incubated for 18 h at 37°C. 10 µL of 0.25%
(3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl-tetrazolium
bromide (MTT) was added to each well subsequent to
incubation for another 30 min. A colour change from
yellow to blue indicated the presence of viable bacteria.
MIC was recorded as the lowest concentration with no
colour changes. The minimum bactericidal concentration
(MBC) was determined by streaking a loopful of mixture
from each well with no colour changes onto agar and
incubated at 37°C for 24 h. MBC was recorded as the lowest
concentration with no bacterial growth.
CHECKERBOARD ASSAY
The antimicrobial combination effects between
graveoline and either erythromycin or vancomycin were
studied following the CLSI 2006 guideline with some
modifications. Two-fold serial dilutions of graveoline and
antibiotic alone were performed in a volume of 20 μL per
well in the first column and row of a 96-well microtiter
plate, respectively. For graveoline-antibiotic combination,
10 uL of each concentration of a serially diluted antibiotic
solution was put in each well of the same remaining row of
the plate. Then, each well was added with 180 μL of 100
fold diluted inoculum. After 60 min incubation at room
temperature, 10 μL of each concentration of a serially
diluted graveoline solution was added in each well of the
same column, so that each row contained a fixed amount
of antibiotic while decreasing amounts of graveoline.
All plates were incubated at 37°C for 18 h and the MIC
values were confirmed by 0.25% MTT. The fractional
inhibitory concentration (FIC) and the FIC indices (FICI)
were calculated and interpreted following Orhan et al.
(2005). The results were determined from the majority of
three independent tests. The procedure was repeated for
ciprofloxacin-antibiotic combination where ciprofloxacin
1. Antimicrobial bioautographic profile of fraction R10 of R. angustifolia leaves alkaloidal extract showing RA9 or
graveoline as the active alkaloid of the fraction, (a) and (b) reference chromatograms viewed under UV254 and UV365 light,
respectively, (c) reference chromatogram sprayed with Dragendorff’s reagent (d), (e) & (f) bioautograms against S. aureus
ATCC 25923, E. faecalis ATCC 29212 and E. coli ATCC 25922, respectively. Chromatographic conditions: pre-coated
aluminium silica gel 60 F254 of 0.2 mm thickness, solvent system, CH2Cl2:MeOH (9:1)
FIGURE
2432
was used as the reference for quinolone antimicrobial
agent.
RESULTS AND DISCUSSION
Antimicrobial bioautography-guided isolation of alkaloidal
fractions of R. angustifolia leaves has led to the
identification of a major active alkaloid identified as
graveoline (3) together with arborinine (1) and the minor
alkaloid, skimmianine (2) (Figures 1 & 2). Graveoline
possessed MIC values of 500 µg/mL against E. faecalis
and 1000 µg/mL for S. aureus and E. coli (Table 1). The
susceptibility values are within the range regarded for
antimicrobial active phytochemicals (Monte et al. 2014).
Antimicrobial active alkaloids may possess different
mechanism of action than those of antibiotics which
might potentiate the activity of the later when used in
combination (Cushnie et al. 2014). Therefore, combination
of graveoline, a natural 4-quinolone alkaloid with either
erythromycin, a macrolide or vancomycin, a glycopeptide
was performed with the objective of achieving higher
efficacy in their activity with desirable synergistic effect
possible for preventing drug resistance in the future. The
combination effects were compared to that of ciprofloxacin
which is a synthetic quinolone antimicrobial agent.
Graveoline possesses a structural characteristic of
quinolone antimicrobial agent by bearing completely
aromatic 4-quinolone ring with specific substituents at
C-1, C-5 and C-8 but lacking in a 4-pyridone ring with
3-carboxyl group which is the essential pharmacophore for
exerting significant antibacterial activity (Chung et al. 2015;
Emami et al. 2005). Nevertheless, it could be presumed
that graveoline might possesses a few characteristics
mechanism of action of the quinolones although at weaker
activity. The graveoline-antibiotic interactions against S.
aureus, E. faecalis and E. coli were recorded as synergy,
partial synergy, additive and indifference, respectively,
based on their FICI values (Orhan et al. 2005) (Table 2). The
MICs of both graveoline and antibiotics were substantially
reduced although to a variable extent as compared to the
values when tested alone against S. aureus and E. coli.
S. aureus was the most susceptible microbe towards
graveoline-antibiotic interactions.
Graveoline-erythromycin combination resulted in
synergy effect with the FICI of 0.37 and reduced MIC by
TABLE 1.
2. Antimicrobial active alkaloids of Ruta angustifolia
6-folds and 4-folds for graveoline and erythromycin,
respectively. Graveoline-vancomycin interaction produced
partial synergy effect with FICI value of 0.5. Erythromycin
and vancomycin are clinically used antibiotics particularly
against Gram-positive bacterial infections. Erythromycin
disrupts protein synthesis by inhibiting peptide elongation
on the ribosome (Gaynor & Mankin 2003) whereas
vancomycin is an inhibitor to cell wall peptidoglycan
synthesis (Kang & Park 2015). The combination effects
could be attributed to the dual actions of both agents at
different target sites of the bacterial cells. Indifference
effect with 2-folds reduction to the MIC of erythromycin
Quantitative antimicrobial activity of graveoline from R. angustifolia and
selected antibiotic standards
Test compound
Graveoline
Ciprofloxacin
Erythromycin
Vancomycin
FIGURE
Antimicrobial Activity (μg/mL)
S. aureus
E. faecalis
E. coli
MIC
MBC
MIC
MBC
MIC
MBC
1000
0.195
1.098
2.50
>1000
0.195
1.098
2.50
500
1.562
0.78
3.13
1000
1.562
0.78
3.13
1000
0.039
50
250
>1000
0.039
50
500
2433
TABLE
2. Antimicrobial combination effects between graveoline and either erythromycin or vancomycin against S. aureus ATCC
25923, E. faecalis ATCC 29212 and E. coli ATCC 25922 with comparison to that of ciprofloxacin
Bacteria
Combination
Graveoline
Erythromycin
S. aureus
ATCC 25923
Graveoline
Vancomycin
Ciprofloxacin
Erythromycin
Ciprofloxacin
Vancomycin
E. faecalis
ATCC 29212
E. coli
ATCC 25922
MIC alone
MIC in combination
1000
1.098
125
0.274
(μg/mL)
1000
2.50
0.195
1.098
0.195
2.50
(μg/mL)
250
0.625
0.098
0.547
0.098
1.25
FIC
FICI
Combination effect
0.12
0.25
0.37
Synergy
0.50
Partial synergy
1.00
Additive
0.50
0.50
1.00
Additive
0.25
0.25
0.50
0.50
Graveoline
Erythromycin
500
0.781
500
0.39
1.00
0.50
1.50
Indifference
Graveoline
Vancomycin
500
3.13
500
3.13
1.00
1.00
2.00
Indifference
Ciprofloxacin
Erythromycin
1.562
0.781
0.781
0.39
0.50
0.50
1.00
Additive
Ciprofloxacin
Vancomycin
1.562
3.125
0.781
1.562
0.50
0.50
1.00
Additive
Graveoline
Erythromycin
1000
50
250
25
0.25
0.50
0.75
Partial synergy
Graveoline
Vancomycin
1000
250
250
125
0.25
0.50
0.75
Partial synergy
Ciprofloxacin
Erythromycin
0.039
50
0.019
1.562
0.50
0.03
0.53
Partial synergy
Ciprofloxacin
Vancomycin
0.039
250
0.002
7.813
0.05
0.13
0.18
Synergy
FICI < 0.5, synergy; 0.5 - 0.75, partial synergy; > 0.75 to 1.0, additive effect; > 1.0 to 4.0 indifference and > 4, antagonism (Orhan et al. 2005)
was produced in graveoline-antibiotic combinations
against E. faecalis. The results showed that graveolineantibiotic actions occurred at a different susceptibility
degree against different bacteria.
Both graveoline-antibiotic combinations against E.
coli indicated a partial synergy with 4-folds reduction
in the MIC of graveoline and 2-folds reduction of both
erythromycin and vancomycin. Although vancomycin is
considered inactive against Gram-negative bacteria due
to variety of mechanisms involve in its cell wall synthesis
and factors that affect membrane permeability (Kang
& Park 2015), the resulted partial synergy effect for its
combinations with graveoline suggested for effective
combination for glycopeptide against Gram-negative E.
coli. The partial synergy could be attributed to the actions
of both agents at different targets consisting of disruption
of cell wall synthesis by vancomycin which increase
membrane permeability of graveoline to its target sites
while inhibition of protein synthesis by erythromycin
enhanced graveoline activity.
Combinations involving ciprofloxacin have resulted
in additive interaction by which in every combination,
both combined antibiotics exhibited 2-folds of MIC
reduction and thus gave the FIC index of 1.00 against both
Gram-positive S. aureus and E. faecalis. The result is
in agreement to the previous finding on the influence of
non-quinolone antimicrobial agents such as macrolides
(Gradelski et al. 2001) and glycopeptides (Noviello et
al. 2001) which demonstrated additive interactions with
ciprofloxacin by all dual drug combinations. In E. coli,
ciprofloxacin-erythromycin combination achieved partial
synergy by 32-folds reduction in the MIC of erythromycin.
A synergistic interaction was achieved for ciprofloxacin
and vancomycin combination with 16-folds reduction of
the MIC of the former and enhancement of the antimicrobial
activity of the later by 32-folds. Ciprofloxacin is a broad
spectrum antibiotic which is more susceptible to Gramnegative bacteria than Gram-positive bacteria. It rapidly
inhibits bacterial growth by primarily interfering with the
DNA synthesis in combination with its efficient membrane
permeability (Cramariuc et al. 2012) which resulted to a
noticeable reduction of erythromycin and vancomycin.
The findings showed that graveoline was a synergistic
enhancer to erythromycin which is superior combination
2434
agent than ciprofloxacin against S. aureus whereas it was
inferior agent than ciprofloxacin against E. coli.
The identification details of the isolated antimicrobial
alkaloids are shown as follows:
Compound 1 2,3-dimethoxy-1-hydroxy-10-methylacridone
[Arborinine]; C16H15NO4; MW: 285 g/mol; bright yellow
fine needle-shaped crystals; MP: 175-176ºC, Rf: 0.67
(CHCl3); IR (CHCl3) cm-1: 1641, 1591, 1556, 1463, 1322,
1251, 1188, 1139, 1106, 1058, 989, 918, 849, 784, 753;
UV/Vis λmax (MeOH) nm (log ε): 230 (3.79), 274 (4.24),
399 (3.41); 1H NMR (500 MHz, CDCl3): 14.73 (1H, s,
1-OH), 8.39 (1 H, dd, J = 1.7 and 8.2 Hz, H-8), 7.70 (1H,
m, H-6), 7.47 (1H, d, J = 8.6 Hz, H-5), 7.26 (1H, t, J =
7.4 Hz, H-7), 6.24 (1H, s, H-4), 4.00 (3H, s, 2-OMe), 3.92
(3H, s, 3-OMe), 3.82 (3H, s, N-Me); 13C NMR (100 MHz,
CDCl3) δ: 180.6 (C-9), 159.2 (C-3) 155.9 (C-1), 141.8
(C-10a), 140.3 (C-4a), 133.9 (C-6), 130.0 (C-2), 126.4 (C8), 121.4 (C-7), 120.50 (C-8a), 114.6 (C-5), 105.6 (C-9a),
86.7 (C-4), 60.8 (2-OCH3), 55.9 (3-OCH3), 34.0 (N-CH3);
MS (EI, 70 eV): m/z (%) = 285 [M + H+] (52), 270 (100),
256 (15), 242 (85), 227 (5), 212 (12), 199 (59), 171 (12),
143 (9), 115 (10).
Compound 2 4,7,8-trimethoxyfuro[2,3-b]quinoline
[Skimmianine]; Formula: C14H13NO4 MW: 259 g/mol,
colorless rhombohedral prisms; MP: 175-176ºC; Rf: 0.52
(CHCl3); IR (CHCl3) cm-1: 1616, 1575, 1389, 1364, 1266,
1088, 950; UV/Vis λmax (MeOH) nm (log ε): 250 (4.30),
332 (3.39); 1H NMR (500 MHz, CDCl3): 8.03 (1 H, d, J =
9.5 Hz, H-5), 7.61 (1H, d, J = 2.5 Hz, H-2), 7.25 (1 H, d, J
= 9.5 Hz, H-6), 7.06 (1 H, d, J = 2.5 Hz, H-3), 4.45 (3 H, s,
4-OMe), 4.14 (3 H, s, 8-OMe), 4.05 (3 H, s, 7-OMe); 13C
NMR (100 MHz, CDCl3) δ: 164.6 (C-9a), 157.5 (C-4), 152.4
(C-8a), 143.1 (C-2), 142.1 (C-7), 141.2 (C-8), 118.3 (C-5),
115.1 (C-3a), 112.1 (C-6), 104.7 (C-3), 102.1 (C-4a), 61.7
(8-OCH3), 59.1 (4-OCH3), 56.8 (7-OCH3); MS (EI, 70 eV):
m/z (%) = 259 [M + H+] (64), 230 (5), 216 (4), 172 (2).
Compound 3 1-methyl-2-[3’,4’-methylenedioxyphenyl]-4quinolone [Graveoline]; Formula: C18H17O3N; MW: 279 g/
mol; white amorphous powder; MP: 185-186ºC; Rf: 0.58
(CHCl3: MeOH, 9:1); IR (CHCl3) cm-1: 1621, 1597, 1563,
1486, 1446, 1250, 1036, 827, 760; UV/Vis λmax (MeOH) nm
(log ε): 243 (4.18), 324 (3.89), 336 (3.90); 1H NMR (500
MHz, CDCl3): 8.50 (1 H, dd, J = 1.5 and 8.0 Hz, H-5),
7.74 (1 H, t, J = 8.5 Hz, H-7), 7.57 (1 H, d, J = 8.5 Hz,
H-8), 7.40 (1H, t, J = 8.0 Hz, H-6), 6.88 (1H, d, J = 1.5 Hz,
H-2’), 6.91 (1H, s, H-3’), 6.88 (1H, d, J = 1.5, H-6’), 6.37
(1H, s, H-3), 6.09 (2H, s, OCH2O), 3.70 (3H, s, N-Me);
13
C NMR (100 MHz, CDCl3) δ: 177.3 (C-4), 154.7 (C-2),
148.8 (C-4’), 147.9 (C-5’), 141.9 (C-8a), 132.5 (C-2’),
129.3 (C-1’), 126.7 (C-4a), 126.6 (C-7), 123.9 (C-6), 122.8
(C-5), 116.1 (C-8), 112.5 (C-3), 109.0 (C-3’), 108.7 (C-6’),
101.8 (OCH2O), 37.5 (N-CH3); MS (EI, 70 eV): m/z (%) =
279 [M + H+] (60), 251 (100), 192 (17).
CONCLUSION
The synergistic action of the combination between
graveoline, a natural quinolone alkaloid and erythromycin,
a macrolide or vancomycin, a glycopeptide possesses a
potential clinical significance as an alternative antimicrobial
combination agent to be further researched for future
benefit in overcoming or at least delaying the emergence
of resistance in bacteria particularly against S. aureus.
ACKNOWLEDGEMENTS
A special gratitude is acknowledged to the Ministry
of Higher Education Malaysia (MOHE) for funding the
research through Fundamental Research Grant Scheme
( FRGS0207-60) and International Islamic University
Malaysia for the publication support (RIGS16-123-0287).
REFERENCES
Abreu, A.C., McBain, A.J. & Simões, M. 2012. Plants as sources
of new antimicrobials and resistance-modifying agents.
Natural Product Reports 29(9): 1007-1021.
Chung, P.Y., Bian, Z.X., Pun, H.Y., Chan, D., Chan, A.S.C., Chui,
C.H., Tang, J.C.O. & Lam, K.H. 2015. Recent advances in
research of natural and synthetic bioactive quinolines. Future
Medicinal Chemistry 7(7): 947-967.
CLSI. 2006. Methods for Dilution Antimicrobial Susceptibility
Tests for Bacteria that Grow Aerobically, Approved Standard,
7th edition, document M7-A7 [ISBN 1-56238-587-9]. Wayne,
Clinical and Laboratory Standards Institute.
Cramariuc, O., Rog, T., Javanainen, M., Monticelli, L.,
Polishchuk, A.V. & Vattulainen, I. 2012. Mechanism of
translocation of fluoroquinolones across lipid membranes.
Biochimica et Biophysica Acta 1818: 2563-2572.
Cushnie, T.P., Cushnie, B. & Lamb, A.J. 2014. Alkaloids: An
overview of their antibacterial, antibiotic-enhancing and
antivirulence activities. Int. J. Antimicrob. Agents 44(5):
377-386.
da Silva, M.F.G.F., Fernandes, J.B., Forim, M.R., Vieira, P.C. &
de Sa, I.G.C. 2013. Alkaloids derived from anthranilic acid:
Quinoline, acridone, and quinazoline in Natural Product,
edited by Ramawat, K.G. & Merillon, J.M. Berlin Heidelberg:
Springer-Verlag. pp: 715-858.
El Sayed, K., Al-Said, M.S., El-Feraly, F.S. & Ross, S.A. 2003.
New quinoline alkaloid from Ruta chalepensis. Journal of
Natural Product 63: 995-997.
Emami, S., Shafiee, A. & Foroumadi, A. 2005. Quinolones:
Recent structural and clinical development. Iranian Journal
of Pharmaceutical Research 3: 123-136.
Gaynor, M. & Mankin, A.S. 2003. Macrolide antibiotics: Binding
site, mechanism of action, resistance. Current Topics in
Medicinal Chemistry 3: 949-961.
Gradelski, E., Kolek, B., Bonner, D.P., Valera, L., Minassian,
B. & Fung-Tomc, J. 2001. Activity of gatifloxacin and
ciprofloxacin in combination with other antimicrobial agents.
International Journal Antimicrobial Agents 17: 103-107.
Hemaiswarya, S. & Doble, M. 2010. Synergistic interaction of
phenylpropanoids with antibiotics against bacteria. Journal
of Medical Microbiology 59: 1469-1476.
Kang, H.K. & Park, Y. 2015. Glycopeptide antibiotics: Structure
and mechanisms of action. Journal of Bacteriology and
Virology 45(2): 67-78.
2435
Koh, H.L., Chua, T.K. & Tan, C.H. 2009. A Guide to Medicinal
Plants: An Illustrated, Scientific and Medicinal Approach.
Singapore: World Scientific. p. 135.
Kyaw, B.M., Shuchi, A.S. & Lim, C.S. 2012. Bactericidal
antibiotic-phytochemical combinations against methicillin
resistant Staphylococcus aureus. Brazilian Journal of
Microbiology 43(3): 938-945.
Linda, E., Maya, A.F., Shannon, B.F., Jan, W., Brian, K.C.,
Mike, T., Eric, D.B. & Gerard, D.W. 2011. Combinations
of antibiotic and non-antibiotic drugs enhance antimicrobial
efficacy. Nature Chemical Biology 7: 348-350.
Monte, J., Abreu, A.C., Borges, A., Simões, L.C. & Simões,
M. 2014. Antimicrobial activity of selected phytochemicals
against Escherichia coli and Staphylococcus aureus and their
biofilms. Pathogen 3: 473-498.
Noviello, S., Ianniello, F. & Esposito, S. 2001. In vitro activity
of LY333328 (oritavancin) against Gram-positive aerobic
cocci and synergy with ciprofloxacin against enterococci. J.
Antimicrobial Chemotherapy 48: 283-286.
Orhan, G., Bayram, A., Zer, Y. & Balci, I. 2005. Synergy tests by E
test and checkerboard methods of antimicrobial combinations
against Brucella melitensis. Journal of Clinical Microbiology
43(1): 140-143.
Rahalison, L., Hamburger, M. & Hostettman, K.A. 1991.
Bioautographic agar overlay method for the detection of
antifungal compounds from higher plants. Phytochemical
Analysis 2: 199-203.
Raj, M.P., Arora, L. & Kumar, N.A. 2013. Phytochemicals
extraction of alkaloids from Ruta graveolens (Snake repellent
plant) and evaluation of its antibacterial and antifungal
activity. International Journal of Biological Research 1(1):
1-10.
Shamsul, K., Tajuddin, A.M. & Mazina, M.Y. 2003. Tumbuhan
Ubatan Tradisional Malaysia. Serdang: Institut Biosains
Universiti Putra Malaysia. p. 87.
Tamma, P.D., Cosgrove, C.E. & Finch, R. 2012 Combination
therapy for treatment of infections with Gram-negative
bacteria. Clinical Microbiology Review 25(3): 450-470.
World Health Organization (WHO). 2017. Antimicrobial
Resistance. Fact Sheet No. 194. http://www.who.int/
mediacentre/factsheets/fs194/en/. Accessed on January 7,
2018.
Laina Zarisa Mohd Kamal, Norazian Mohd Hassan*
& Nurhaya Md Taib
Department of Pharmaceutical Chemistry
Kulliyyah of Pharmacy
International Islamic University Malaysia
25200 Kuantan, Pahang Darul Makmur
Malaysia
May Khin Soe
Department of Basic Medical Sciences
Kulliyyah of Pharmacy
International Islamic University Malaysia
25200 Kuantan, Pahang Darul Makmur
Malaysia
*Corresponding author; email: norazianmh@iium.edu.my
Received: 9 April 2017
Accepted: 7 June 2018